Organization | CSL Behring

CSL Behring Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: King of Prussia PA United States (2004)

Organization Overview

First Clinical Trial

2004

NCT00640289

First Marketed Drug

2004

albumin (Human) (Plasbumin)

First NDA Approval

2009

fibrinogen (human) (RiaSTAP)

Last Known Activity

2023

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CSL Behring | CSL Behring AG | CSL Behring - Director, Medical Affairs Cardiovascular | CSL Behring GmbH | CSL Behring K.K. | CSL Behring Lengnau AG | CSL Behring LLC | CSL Innovation Pty Ltd | CSL Limited | CSL Plasma | Joshua S. Jacobs, MD | Seqirus | Seqirus Inc. | Seqirus Pty Ltd. | Seqirus Vaccines Limited

Active Ingredients

Marketed Drugs (15)

Key: CSL Behring (14) Acquired (1)

albumin (Human) (Plasbumin) (1976)

alpha-1 antitrypsin (Prolastin) (2003)

antihemophilic factor viii human (Hemofil M) (2000)

antihemophilic factor viii (Recombinant), single chain (Afstyla) (2016 NDA)

C1 Esterase Inhibitor (Human) (Cinryze) (2009)

etranacogene dezaparvovec (Hemgenix) (2022 NDA)

factor ix albumin fusion protein (Idelvion) (2016 NDA)

factor xiii concentrate (human) (Corifact) (2011 NDA)

fibrinogen (human) (RiaSTAP) (2009 NDA)

human coagulation factor ix (Mononine) (2000)

human factor ix complex (prothrombin complex concentrate) (Bebulin) (2013)

immune globulin (human) (Gamastan) (2000)

inactivated influenza vaccine (1998)

Rho(D) Immune Globulin Intravenous (Human) (WinRho) (2004)

von Willebrand factor (Wilate) (2000)

Drugs in Phase 4 Trials (23)

Key: CSL Behring (11) Acquired (12)

alpha-1 antitrypsin (Prolastin) (8 trials)

antihemophilic factor viii human (Hemofil M) (5 trials)

blood plasma (5 trials)

C1 Esterase Inhibitor (Human) (Cinryze) (11 trials)

cytomegalovirus immune globulin intravenous (human) (cytogam) (2 trials)

epoetin (Epogen) (1 trial)

ferric carboxymaltose (Injectafer) (28 trials)

ferric sulfate (1 trial)

ferrous fumarate (3 trials)

ferrous sulfate (3 trials)

fibrinogen (human) (RiaSTAP) (12 trials)

human factor ix complex (prothrombin complex concentrate) (Bebulin) (10 trials)

icosapent ethyl (vascepa) (2 trials)

immune globulin (human) (Gamastan) (40 trials)

inactivated influenza vaccine (38 trials)

iron dextran (INFeD) (2 trials)

netupitant (Akynzeo) (1 trial)

omega-6 fatty acids (2 trials)

sodium chloride (13 trials)

tivantinib (6 trials)

valganciclovir (Valcyte) (1 trial)

von Willebrand factor (recombinant) (Vonvendi) (5 trials)

Drugs in Phase 3 Trials (39)

Key: CSL Behring (16) Acquired (23)

acov2 (1 trial)

albumin (Human) (Plasbumin) (1 trial)

albutrepenonacog alfa (3 trials)

antihemophilic factor viii (Recombinant) (Adynovate) (1 trial)

antihemophilic factor viii (Recombinant), single chain (Afstyla) (3 trials)

apolipoprotein (7 trials)

azathioprine (imuran) (1 trial)

Bacterial Lysates (pulmonarom) (1 trial)

betamethasone (celestone) (1 trial)

calcium (2 trials)

carboplatin (paraplatin) (1 trial)

clazakizumab (5 trials)

coagulation factor viia (recombinant) (NovoSevenRT) (3 trials)

csl689 (2 trials)

cyclophosphamide (cytoxan) (3 trials)

desflurane (suprane) (1 trial)

difelikefalin (Korsuva) (2 trials)

doxorubicin (Doxil) (1 trial)

epirubicin (ellence) (1 trial)

etranacogene dezaparvovec (Hemgenix) (1 trial)

factor xiii concentrate (human) (Corifact) (5 trials)

garadacimab (9 trials)

human immunoglobulin g (1 trial)

influenza vlp vaccine (1 trial)

iron sucrose (venofer) (1 trial)

mf59 (5 trials)

mycophenolate (CellCept) (7 trials)

origanum dictamnus l (1 trial)

paclitaxel (taxol) (1 trial)

patiromer (veltassa) (3 trials)

pertuzumab (perjeta) (1 trial)

polynuclear iron(iii)-oxyhydroxide (Velphoro) (9 trials)

reslizumab (cinqair) (1 trial)

salvia (1 trial)

sevelamer (renagel) (3 trials)

snf472 (3 trials)

thymbra (1 trial)

trastuzumab (herceptin) (1 trial)

von Willebrand factor (Wilate) (6 trials)

Drugs in Phase 2 Trials (16)

Key: CSL Behring (12) Acquired (4)

ah5n6c (2 trials)

aIIV-B (HepliSav B) (1 trial)

autologous platelets (1 trial)

cal-1 (lvsh5/c46) (1 trial)

cal-1 modified cd4+ t lymphocytes (1 trial)

cal-1 modified hspc (1 trial)

csl 311 (1 trial)

CSL324 (4 trials)

csl346 (1 trial)

csl412 (1 trial)

csl425 (4 trials)

factor ix albumin fusion protein (Idelvion) (2 trials)

h5n1 antigen (1 trial)

high density lipoprotein (1 trial)

platelets (1 trial)

vit-2763 (4 trials)

Drugs in Phase 1 Trials (21)

Key: CSL Behring (14) Acquired (7)

apixaban (eliquis) (1 trial)

arct-2138 (1 trial)

cd34+ cells transduced with lentiviral vector encoding human γ-globing16d and short-hairpin rna734 (1 trial)

coagulation factor ix (Recombinant) (Rixubis) (1 trial)

cr002 (1 trial)

csl040 (1 trial)

CSL311 (1 trial)

csl-360 (1 trial)

csl362 (1 trial)

csl730 (2 trials)

csl787 (1 trial)

csl830 (2 trials)

digoxin (lanoxin) (1 trial)

furosemide (lasix) (1 trial)

hemopexin (1 trial)

human coagulation factor ix (Mononine) (1 trial)

losartan (cozaar) (1 trial)

omeprazole (prilosec) (1 trial)

sa-mrna (1 trial)

sars-cov-2 hyperimmune globulin (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Other Trials (3)

Key: CSL Behring (2) Acquired (1)

folic acid (1 trial)

salmonella typhi polysaccharide vaccine (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Coronary Syndrome (Phase 3)

Afibrinogenemia (Phase 3)

Agammaglobulinemia (Phase 4)

alpha 1-Antitrypsin Deficiency (Phase 4)

Anemia, Sickle Cell (Phase 1)

Aneurysm (Phase 4)

Angioedema (Phase 4)

Angioedemas, Hereditary (Phase 4)

Aortic Aneurysm (Phase 2)

Aortic Aneurysm, Abdominal (Phase 4)

Aortic Valve Stenosis (Phase 2)

Asthma (Phase 1)

Autoimmune Diseases (Phase 1)

Blood Coagulation Disorders (Phase 4)

Blood Loss, Surgical (Phase 4)

Blood Platelet Disorders (Phase 4)

Bone Marrow Diseases (Phase 4)

Bronchiectasis (Phase 1)

Cerebral Infarction (Phase 1)

Common Variable Immunodeficiency (Phase 4)

Communicable Diseases (Phase 2)

Constriction, Pathologic (Phase 2)

Coronary Artery Disease (Phase 2)

Coronavirus Infections (Phase 2)

Cystic Fibrosis (Phase 1)

Cytomegalovirus Infections (Phase 4)

Dermatomyositis (Phase 3)

Diabetic Nephropathies (Phase 2)

Disease (Phase 4)

Emphysema (Phase 4)

Encephalitis (Phase 3)

Factor VII Deficiency (Phase 1)

Factor XIII Deficiency (Phase 3)

Fasciitis (Phase 2)

Fasciitis, Necrotizing (Phase 2)

Fibrosis (Phase 1)

Fournier Gangrene (Phase 2)

Gangrene (Phase 2)

Gas Gangrene (Phase 2)

Graft vs Host Disease (Phase 3)

Heart Diseases (Phase 3)

Heart Failure (Phase 3)

Heart Valve Diseases (Phase 2)

Hematologic Diseases (Phase 4)

Hemophilia A (Phase 4)

Hemophilia B (Phase 3)

Hemorrhage (Phase 4)

Hemostatic Disorders (Phase 4)

Hereditary Angioedema Types I and II (Phase 4)

Hidradenitis (Phase 1)

Hidradenitis Suppurativa (Phase 1)

IgG Deficiency (Phase 3)

Immunologic Deficiency Syndromes (Phase 4)

Infarction (Phase 2)

Infections (Phase 2)

Inflammation (Phase 2)

Influenza, Human (Phase 4)

Influenza in Birds (Phase 3)

Ischemia (Phase 1)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 4)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lung Diseases, Obstructive (Phase 2)

Lymphoma (Phase 2)

Muscle Weakness (Phase 2)

Myasthenia Gravis (Phase 3)

Myocardial Infarction (Phase 2)

Neuritis (Phase 2)

Pneumonia (Phase 2)

Polyneuropathies (Phase 4)

Polyradiculoneuropathy (Phase 3)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 4)

Postoperative Hemorrhage (Phase 3)

Postpartum Hemorrhage (Phase 2)

Psoriasis (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Pulmonary Emphysema (Phase 4)

Purpura (Phase 4)

Purpura, Thrombocytopenic (Phase 4)

Purpura, Thrombocytopenic, Idiopathic (Phase 4)

Renal Insufficiency (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Sinusitis (Phase 3)

Soft Tissue Infections (Phase 2)

Spinal Cord Diseases (Phase 4)

Stroke (Phase 1)

Syndrome (Phase 3)

Thrombosis (Phase 2)

von Willebrand Diseases (Phase 4)

Wounds and Injuries (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 272
# of Trial APIs: 102